Tribendimidine
Clinical data | |
---|---|
ATC code | none |
Identifiers | |
| |
CAS Number | 115103-15-6 |
PubChem (CID) | 3086564 |
ChemSpider | 2343161 |
ChEMBL | CHEMBL427256 |
Chemical and physical data | |
Formula | C28H32N6 |
Molar mass | 452.594 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Tribendimidine is a broad-spectrum anthelmintic agent developed in China, at the National Institute of Parasitic Diseases in Shanghai. It is a derivative of amidantel.[1]
In clinical trials, it was highly effective in treating ankylostomiasis, ascariasis and enterobiasis.[2] However, animal studies suggest it is ineffective in treating Schistosoma mansoni or Fasciola hepatica disease.[1]
Tribendimidine is associated with Shandong Xinhua Pharmaceutical Company Limited in Zibo, Shandong, China.
References
- 1 2 Keiser J, Shu-Hua X, Chollet J, Tanner M, Utzinger J (2007). "Evaluation of the in vivo activity of tribendimidine against Schistosoma mansoni, Fasciola hepatica, Clonorchis sinensis, and Opisthorchis viverrini". Antimicrob Agents Chemother. 51 (3): 1096–8. doi:10.1128/AAC.01366-06. PMC 1803157. PMID 17194822. Free full text.
- ↑ Xiao SH, Hui-Ming W, Tanner M, Utzinger J, Chong W (2005). "Tribendimidine: a promising, safe and broad-spectrum anthelmintic agent from China". Acta Trop. 94 (1): 1–14. doi:10.1016/j.actatropica.2005.01.013. PMID 15777691.
This article is issued from Wikipedia - version of the 6/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.